Safety & Recalls

August 7th 2025

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing reports indicated there is a risk of neurologic and cardiac events in people over the age of 60.

July 22nd 2025

Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.

July 19th 2025

Elevidys is a gene therapy approved to treat Duchenne muscular dystrophy. Last month, Sarapta halted sales of the therapy for non-ambulatory patients.

July 17th 2025

Some vials in two lots of the antibiotic cefazolin are labeled as being penicillin G potassium, which if used could lead to suboptimal outcomes, adverse events, drug interactions and delayed recovery.